Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
Ribociclib
Medication labelKISQALI is indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive,…
Why this: Advisory · dailymed-prescription
KISQALI is indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. KISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy.
- generic_name
- ribociclib
- product_names
- ribociclib
- ndc
- 0078-0860, 0078-0860-01, 0078-0867, 0078-0867-14, 0078-0867-42, 0078-0874, 0078-0874-21, 0078-0874-63
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en